株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Millennium Pharmaceuticals, Inc. - 製品パイプライン分析

Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 251690
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
Millennium Pharmaceuticals, Inc. - 製品パイプライン分析 Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016
出版日: 2016年12月30日 ページ情報: 英文 61 Pages
概要

Millennium Pharmaceuticals, Inc.は、癌治療薬の研究開発及び商品化を担うバイオ製薬会社です。主力製品である Velcade (bortezomib) は、多発性骨髄腫と再発性マントル細胞リンパ腫の治療のために開発されました。同社製品には様々なタイプの癌をターゲットにした15種類以上の腫瘍治験化合物があります。

当レポートでは、Millennium Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Millennium Pharmaceuticals, Inc.の基本情報

Millennium Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Millennium Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Millennium Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Millennium Pharmaceuticals, Inc.:パイプライン製品の概況

Millennium Pharmaceuticals, Inc.

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 出願が却下された/取り下げられた製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Millennium Pharmaceuticals, Inc.:薬剤プロファイル

  • bortezomib
  • alisertib
  • brentuximab vedotin
  • ixazomib citrate
  • MLN-0128
  • MLN-2480
  • orteronel
  • MLN-0264
  • MLN-1117
  • MLN-7243
  • pevonedistat hydrochloride
  • TAK-659
  • TAK-733
  • Small Molecules to Inhibit Histone Deacetylase 6 for Cacner

Millennium Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Millennium Pharmaceuticals, Inc.:最近のパイプライン動向

Millennium Pharmaceuticals, Inc.:休止中のプロジェクト

Millennium Pharmaceuticals, Inc.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • alisertib
    • betrixaban
    • bortezomib
    • HuL-2G7
    • orteronel
    • TAK-441
    • TAK-448
    • TAK-901
    • TAK-960
    • tandutinib

Millennium Pharmaceuticals, Inc.:企業発表

Millennium Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08196CDB

Summary

Global Markets Direct's, 'Millennium Pharmaceuticals Inc - Product Pipeline Review - 2016', provides an overview of the Millennium Pharmaceuticals Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Millennium Pharmaceuticals Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Millennium Pharmaceuticals Inc
  • The report provides overview of Millennium Pharmaceuticals Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Millennium Pharmaceuticals Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Millennium Pharmaceuticals Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Millennium Pharmaceuticals Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Millennium Pharmaceuticals Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Millennium Pharmaceuticals Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Millennium Pharmaceuticals Inc Snapshot
    • Millennium Pharmaceuticals Inc Overview
    • Key Facts
  • Millennium Pharmaceuticals Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Millennium Pharmaceuticals Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals Inc - Pipeline Products Glance
    • Millennium Pharmaceuticals Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Millennium Pharmaceuticals Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Millennium Pharmaceuticals Inc - Drug Profiles
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • orteronel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pevonedistat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sapanisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • serabelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-243 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-931 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Millennium Pharmaceuticals Inc - Pipeline Analysis
    • Millennium Pharmaceuticals Inc - Pipeline Products by Target
    • Millennium Pharmaceuticals Inc - Pipeline Products by Route of Administration
    • Millennium Pharmaceuticals Inc - Pipeline Products by Molecule Type
    • Millennium Pharmaceuticals Inc - Pipeline Products by Mechanism of Action
  • Millennium Pharmaceuticals Inc - Dormant Projects
  • Millennium Pharmaceuticals Inc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • alisertib
      • betrixaban
      • bortezomib
      • HuL-2G7
      • indusatumab vedotin
      • IPI-443
      • orteronel
      • TAK-441
      • TAK-733
      • TAK-901
      • TAK-960
      • tandutinib
  • Millennium Pharmaceuticals Inc - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Millennium Pharmaceuticals Inc, Key Facts
  • Millennium Pharmaceuticals Inc - Pipeline by Indication, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Stage of Development, 2016
  • Millennium Pharmaceuticals Inc - Monotherapy Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Millennium Pharmaceuticals Inc - Phase II, 2016
  • Millennium Pharmaceuticals Inc - Phase I, 2016
  • Millennium Pharmaceuticals Inc - Preclinical, 2016
  • Millennium Pharmaceuticals Inc - Discovery, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Target, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Route of Administration, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Molecule Type, 2016
  • Millennium Pharmaceuticals Inc - Pipeline Products by Mechanism of Action, 2016
  • Millennium Pharmaceuticals Inc - Dormant Developmental Projects,2016
  • Millennium Pharmaceuticals Inc - Discontinued Pipeline Products, 2016

List of Figures

  • Millennium Pharmaceuticals Inc - Pipeline by Top 10 Indication, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Stage of Development, 2016
  • Millennium Pharmaceuticals Inc - Monotherapy Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Out-Licensed Products in Pipeline, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Top 10 Target, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Route of Administration, 2016
  • Millennium Pharmaceuticals Inc - Pipeline by Molecule Type, 2016
  • Millennium Pharmaceuticals Inc - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top